Cormica, a global medical device and pharmaceuticals testing group, has acquired Focus Laboratories, a microbiological testing firm with facilities in Allentown, PA, and Palm Harbor, FL.

This follows Cormica’s acquisition of Zwisler Laboratorium in Reichenau, in Germany and furthers Cormica’s strategic goal of expanding its footprint across the U.S. and Europe.

Focus Laboratories specializes in microbiological testing, including rapid microbiology and consulting for the pharmaceutical, biotech and medical device sectors.

Cormica helps life science manufacturers and medtech innovators to launch their products securely, and across more markets. The group has approximately 250 employees based across state-of-the-art lab facilities in the UK, U.S. and Germany.

Focus Laboratories will benefit from Cormica’s New Jersey chemistry facility, TPM Laboratories, enabling it to offer clients a more comprehensive portfolio of tests essential for developing medicines.

Mark Hammond, CEO of Cormica Group, said, “We have had a strong start to 2025, with the acquisition of Zwisler Laboratorium and now Focus Laboratories which underscores our commitment to building a strong presence in the US. Focus has an outstanding reputation in microbiological testing, and we look forward to working closely with Tony Grilli and his team to support their future growth.”

Anthony Grilli, founder of Focus Laboratories, said, “This partnership significantly expands our service offering, giving us access to invaluable resources and expertise that will allow us to serve more of our clients’ evolving needs while maintaining the exceptional quality and reliability they’ve come to expect from us. With a state-of-the-art analytical chemistry lab in New Jersey, we are now able to provide a more comprehensive suite of services.”